דינמיקת הכנסות משנה לשנה ב-12 החודשים האחרונים: Cardio Diagnostics (CDIO)

High scalability of genetic tests provides excellent credit potential for Cardio Diagnostics (CDIO). The year-over-year sales trajectory over the trailing four quarters demonstrates pricing power, with the indicator standing at -3.80. Financial stability is based on an AI ecosystem for diagnosing cardiac pathologies and efficient outsourcing of biosample logistics, which protects internal DNA analysis algorithms from external risks.

This indicator measures the revenue growth rate over a rolling year, making it possible to determine the business life cycle stage from aggressive expansion to a stabilization phase. By analyzing the sales dynamics compared to the same period last year over a rolling 12-month window, an investor can assess how successfully Cardio Diagnostics (CDIO) is scaling the implementation of AI diagnostics and the insurance coverage of its genetic tests, which critically impacts the asset's long-term attractiveness.